Detailed Narrative
2025 Performance and Strategic Investments
Humana reported adjusted EPS of $17.14 for 2025, surpassing its initial guidance of $16.25. This performance was achieved despite making higher-than-planned investments aimed at accelerating the company's transformation and future positioning. The insurance segment's full-year benefit ratio of 90.4% was slightly better than guidance, including a strategic benefit set aside for a potential Doc Fix, which was then reinvested into network management and administrative support for technology.
Quality Membership Growth and Retention
The company experienced significant growth, adding approximately 1 million individual MA members in AEP, a 20% increase. This growth was characterized by improved quality, with retention rates increasing by over 500 basis points year-over-year. Notably, 70% of new sales were switchers from competitor plans, and 75% originated from higher lifetime value channels, marking a 10 percentage point improvement from the prior year. Approximately 30% of new sales were 'bounce back' members, indicating prior engagement with Humana.
Stars Performance and Mitigation Efforts
Humana remains confident in its trajectory to return to Top Quartile Stars results by BY '28. Operational improvements include initiating Stars programs earlier in the year and utilizing data for targeted interventions to close gaps. Early indicators like reduced Medicare complaints (CTMs) and increased Health Risk Assessment (HRA) completion rates in January are positive. Despite these efforts, the company faces a substantial net Stars headwind of approximately $3.5 billion for 2026, partly due to higher retention of 3.5-star contracts and 30% of new sales being on contracts rated below 4-star for BY '26.
Capital Efficiency and Balance Sheet Management
Significant progress has been made in capital optimization, including refining legal entity structures and reinsurance arrangements. These initiatives are expected to offset over $3 billion of growth in capital requirements from 2024 through 2026, effectively funding the 2026 membership growth. Despite an anticipated 40% premium growth from 2024 to 2026, statutory capital requirements are projected to increase by less than 20%, allowing debt-to-capital levels to remain largely flat year-over-year while maintaining credit ratings.
Operating Efficiency and Transformation Initiatives
Humana anticipates significant improvement in its consolidated operating cost ratio for 2026. This is attributed to operating leverage from membership and revenue growth, tactical cost-cutting measures, and broader transformation efforts. Examples include expanding outsourcing capabilities, simplifying processes, and leveraging technology and automation. These multi-year initiatives are designed to drive efficiency and fundamentally change operational approaches, with increasing impact expected from 2026 onwards.
Medicaid and CenterWell Expansion
The Medicaid footprint has expanded to 13 states, with new launches anticipated in Georgia and Texas next year. The CenterWell segment is expected to benefit significantly from the new membership growth in 2026, particularly in CenterWell Pharmacy, CenterWell PCO, and home health volumes, which are projected to provide a positive tailwind to overall margins. The company also hopes to announce a strategic acquisition in the primary care space soon.